Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Lessons on the Role of Partnership in Polio Eradication


Published on

Joel Calmet, MD, MS, Senior Director of Communications, Medical and Scientific, Sanofi Pasteur on Lessons on the Role of Partnership in Polio Eradication at the CCIH 2018 conference.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Lessons on the Role of Partnership in Polio Eradication

  1. 1. Polio eradication Lessons on partnership role and supply change
  2. 2. Sanofi Pasteur is the key industrial partner of Global Polio Eradication Initiative ● Sanofi Pasteur is the largest company entirely dedicated to vaccines ○ 1+ billion doses of vaccines produced each year ○ 500+ million people immunized with our vaccines worldwide ● We have partnerships with several international organisations ○ Vaccines provided in adapted packs and at tiered prices ○ Supplied where they are the most needed 2 We are the largest corporate donor to the Global Polio Eradication Initiative (GPEI) 2,5+ billion children have been immunized since 1988 First worldwide supplier of Inactivated Polio Vaccine (IPV)
  3. 3. Partnerships play a critical role in health systems strengthening ● Eradication is an adventure ○ 30-year effort to eradicate polio ● Requires a diversity of stakeholders and partners ○ Private sector, vaccine suppliers and public organisations, governments, NGOs, FBOs ● Needs relationships with mutual trust, dialogue and partnership ○ Important lessons about the shape of future public-private partnerships 3 Key lessons from GPEI
  4. 4. Implication for future global public health initiatives /1 4 Governance of relationship between private and public sector will require more thought ○ How the private sector becomes a fully integrated partner? ○ How NGOs, FBOs remain independent? ○ How government retains its unique role in governance and setting policy priorities? Regulatory burden are only likely to increase ○ Too many barriers delay the delivery of the high quality vaccines ○ Consistent regulatory standards to be applied quickly and effectively ○ Faith-based institutions role in advocating for this Large scale initiatives have a better fit with multinational corporations than public national players 1 3 2
  5. 5. Implication for future global public health initiatives /2 5 Anticipation of vaccine supply and any added value technology ○ Long-term programs and continuing investments for sustainable immunization ○ Long-term planning and commitments from governments and voluntary sector for efficient and cost effective industry work True collaboration between industry, policy makers and health regulators ○ Required to build a sustainable process to produce and supply vaccines for generations to come 5 4
  6. 6. Thank you Join us for the lunch table on Sunday to continue the discussion on immunization and partnerships